Novartis' radiolabeled somatostatin analog Lutathera, or lutetium Lu 11 dotatate, received expanded approval from the FDA, allowing its use to treat pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors who are at least 12 years old. The decision was based on a Phase 2 study, in which the treatment demonstrated a similar safety profile in patients 12 years to 17 years old and adult patients.